OvaScience to Host Third Quarter 2017 Financial Results Conference Call

WALTHAM, Mass.--(BUSINESS WIRE)-- OvaScienceSM (NASDAQ: OVAS), a fertility company focused on the discovery, development and commercialization of new treatment options, announced today that it will host a conference call at 4:30 p.m. ET on Thursday, November 2, 2017 to discuss third quarter 2017 financial results and provide a general corporate update.

The conference call may be accessed by dialing +1-888-424-8151 for U.S. callers and +1-847-585-4422 for international callers five minutes prior to the start of the call and providing the passcode 9200599. A live webcast of the conference call will be available online from the Investors section of the Company’s website at www.ovascience.com.

A replay of the conference call will be available from 7:00 p.m. ET on Thursday, November 2, 2017, through 11:59 p.m. ET on Thursday, November 16, 2017, and may be accessed by visiting OvaScience’s website or by dialing 1-888-843-7419 for U.S. callers and 1-630-652-3042 for international callers. The replay access code is 9200599#.

About OvaScienceOvaScienceSM, Inc. (NASDAQ: OVAS) is a fertility company dedicated to improving treatment options for women around the world. OvaScience is discovering, developing and commercializing new fertility treatments because it believes women deserve more options. Each OvaScience treatment is based on the Company’s proprietary technology platform that leverages the breakthrough discovery of egg precursor (EggPCSM) cells – immature egg cells found inside the protective ovarian lining. OvaScience is developing OvaPrimeSM, which could increase a woman’s egg reserve and OvaTureSM, a potential in vitro fertilization (IVF) treatment that could help a woman produce healthy, fertilizable eggs without hormone injections. OvaScience’s AUGMENTSM treatment, a fertility option designed to improve IVF success rates, is available in certain IVF clinics in Canada. OvaScience treatments are not available in the United States. For more information, visit www.ovascience.com.

###

View source version on businesswire.com: http://www.businesswire.com/news/home/20171026006173/en/

Media and Investor Contact:
OvaScience
Jennifer Viera, 617-420-8748
[email protected]

Source: OvaScience

You May Also Be Interested In

• FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
• JPMorgan Downgrades Tata Technologies (TATATECH:IN) to Underweight
• Cerebras Q1 EPS miss sends shares down 9% after-hours